老年急性髓系白血病的治疗进展

Abstract
Figure/Table
References (52)
Related Citation (15)

Download: PDF (594 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous myeloid primitive cell clonal malignant proliferative disease that tends to occur in the elderly. The treatment of AML mainly consists of initial induction of remission, followed by consolidation and maintenance therapy after complete remission (CR). Due to physiological age, physical status and other characteristics of elderly AML patients, as well as disease-related factors such as poor cytogenetics, elderly AML patients are characterized by low CR rate, poor prognosis and high early mortality. For elderly AML patients, doctors need to carry out individualized evaluation. In the stage of induced remission, some elderly people are suitable for intensive chemotherapy, while most elderly people are suitable for low-intensity chemotherapy. Some new advances have been made in the treatment of AML in the elderly. In this review, we reviewed the advances in the treatment of elderly AML in order to improve the quality of life of elderly PATIENTS with AML.

Key words： Elderly patients Acute myeloid leukemia Individualized treatment Progress

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LE Lixia
	LI Danhong
	ZHANG Siyuan
	HU Xingyue
	ZHU Lingling

Cite this article:

LE Lixia,LI Danhong,ZHANG Siyuan, et al. Advances in the treatment of acute myeloid leukemia in the elderly[J]. 中国当代医药, 2022, 29(20): 35-39.

URL:

https://www.dangdaiyiyao.com/EN/ OR https://www.dangdaiyiyao.com/EN/Y2022/V29/I20/35

[1]	Winer ES，Stone RM.Novel therapy in Acute myeloid leukemia （AML）：moving toward targeted approaches[J].Ther Adv Hematol，2019，10：2040620719860645.
[2]	Pollyea DA，Bixby D，Perl A，et al.NCCN Guidelines Insights：Acute Myeloid Leukemia[J].J Natl Compr Canc Netw，2021，19（1）：16-27.
[3]	田雪姣，徐颖.地西他滨联合CAG方案治疗老年初治急性髓系白血病的效果[J].河南医学研究，2021，30（1）：86-88.
[4]	汪变红，关伟，吕娜，等.老年急性髓系白血病分子学特征及临床意义[J].中国实验血液学杂志，2020，28（5）：1445-1450.
[5]	Genovese G，K■hler AK，Handsaker RE，et al.Clonal hemato-poiesis and blood-cancer risk inferred from blood DNA sequence[J].N Engl J Med，2014，371（26）：2477-2487.
[6]	Jaiswal S，Fontanillas P，Flannick J，et al.Age-related clonal hematopoiesis associated with adverse outcomes[J].N Engl J Med，2014，371（26）：2488-2498.
[7]	Kantarjian H，O′Brien S.Questions regarding frontline therapy of acute myeloid leukemia[J].Cancer，2010，116（21）：4896-4901.
[8]	Ossenkoppele G，L■wenberg B.How I treat the older patient with acute myeloid leukemia[J].Blood，2015，125（5）：767-774.
[9]	Jackson K，Kennedy G，Mollee P，et al.Intensive chemotherapy and reduced-intensity allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia in elderly patients[J].Asia Pac J Clin Oncol，2014，10（3）：246-254.
[10]	Thomas X.The management and treatment of acute leukemias in the elderly population[J].Expert Rev Hematol，2017，10（11）：975-985.
[11]	Hajji N，Mateos S，Pastor N，et al.Induction of genotoxic and cytotoxic damage by aclarubicin，a dual topoisomerase inhibitor[J].Mutat Res，2005，583（1）：26-35.
[12]	崔高安.阿糖胞苷在成人急性髓细胞白血病巩固化疗中的临床应用[J].当代医学，2020，26（11）：164-165.
[13]	Usuki K，Urabe A，Masaoka T，et al.Efficacy of granulocyte colonystimulating factor in the treatment of acute myelogenous leukaemia：a multicentre randomized study[J].Br J Haematol，2002，116（1）：103-112.
[14]	Thomas X，Raffoux E，Renneville A，et al.Which AML subsets benefit from leukemic cell priming during chemotherapy?Long-term analysis of the ALFA-9802 GM-CSF study[J].Cancer，2010，116（7）：1725-1732.
[15]	申清云，高大.老年急性髓系白血病的治疗方法研究进展[J].新乡医学院学报，2019，36（1）：96-100.
[16]	Wei G，Ni W，Chiao JW，et al.A meta-analysis of CAG （cytarabine，aclarubicin，G-CSF） regimen for the treatment of 1029 patients with acute myeloid leukemia and myelodysplastic syndrome[J].J Hematol Oncol，2011，4（1）：46.
[17]	田婉露，曾庆曙，葛健，等.CAG方案治疗急性白血病和高危骨髓增生异常综合征临床疗效观察[J].安徽医学，2014，35（7）：865-869.
[18]	邓丽娟，黎琰，乔艳红，等.去甲基化药物在急性髓系白血病中的临床应用进展[J].中国新药与临床杂志，2020， 39（6）：329-334.
[19]	于宁，唐一楠，张镭.阿扎胞苷和地西他滨治疗血液系统肿瘤的临床分子学研究进展[J].中国医院用药评价与分析，2020，20（4）：510-512.
[20]	Kantarjian HM，Thomas XG，Dmoszynska A，et al.Multicenter，randomized，open-label，phase Ⅲ trial of decitabine versus patient choice，with physician advice，of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia[J].J Clin Oncol，2012，30（21）：2670-2677.
[21]	Qin T，Youssef EM，Jelinek J，et al.Effect of cytarabine and decitabine in combination in human leukemic cell lines[J].Clin Cancer Res，2007，13（14）：4225-4232.
[22]	谢月，李砚如，赵慧慧，等.地西他滨联合阿糖胞苷对HL60细胞的增殖抑制作用研究[J].临床血液学杂志，2017，30（3）：364-367.
[23]	Scandura JM，Roboz GJ，Moh M，et al.Phase 1 study of epigenetic priming with decitabine prior to standard induction chemotherapy for patients with AML[J].Blood，2011，118（6）：1472-1480.
[24]	Li J，Chen Y，Zhu Y，et al.Efficacy and safety of decitabine in combination with G-CSF，low-dose cytarabine and aclarubicin in newly diagnosed elderly patients with acute myeloid leukemia[J].Oncotarget，2015，6（8）：6448-6458.
[25]	吴艳云，崔思远，郑伟，等.阿扎胞苷联合HAG方案诱导缓解原发多药耐药AML 1例并患者突变景观分析[J].世界最新医学信息文摘，2019，19（16）：254-255，260.
[26]	Smith BD，Beach CL，Mahmoud D，et al.Survival and hospitalization among patients with acute myeloid a treated with azacitidine or decitabine in a large managed care population：a real-world，retrospective，claims-based，comparative analysis[J].Exp Hematol Oncol，2014，3（1）：10.
[27]	Das M.Venetoclax with decitabine or azacitidine for AML[J].Lancet Oncol，2018，19（12）：e672.
[34]	Gallogly MM，Lazarus HM.Midostaurin：an emerging treatment for acute myeloid leukemia patients[J].J Blood Med，2016，7：73-83.
[35]	Thol F，Ganser A.Treatment of Relapsed Acute Myeloid Leukemia[J].Curr Treat Options Oncol，2020，21（8）：66.
[28]	Richard-Carpentier G，Dinardo CD.Venetoclax for the treatment of newly diagnosed acute myeloid leukemia in patients who are ineligible for intensive chemotherapy[J].Ther Adv Hematol，2019，10：204062071988282.
[29]	Di Nardo CD，Pratz K，Pullarkat V，et al.Venetoclax combined with decitabine or azacitidine in treatment-naive，elderly patients with acute myeloid leukemia[J].Blood，2019， 133（1）：7-17.
[30]	Roskoski R Jr.The role of small molecule Flt3 receptor protein-tyrosine kinase inhibitors in the treatment of Flt3-positive acute myelogenous leukemias[J].Pharmacol Res，2020，155（2）：104725.
[31]	Dombret H，Itzykson R.How and when to decide between epigenetic therapy and chemotherapy in patients with AML[J].Hematology Am Soc Hematol Educ Program，2017，2017（1）：45-53.
[32]	Jeon JY，Zhao Q，Buelow DR，et al.Preclinical activity and a pilot phase I study of pacritinib，an oral JAK2/FLT3 inhibitor，and chemotherapy in FLT3-ITD-positive AML[J].Invest New Drugs，2020，38（2）：340-349.
[33]	Zhou Y，Wang X，An YH，et al.Mechanism of Sorafenib and Decitabine Inducing Apoptosis of Diffuse Large B-Cell Lymphoma Cells[J].Zhongguo Shi Yan Xue Ye Xue Za Zhi，2020，28（1）：146-152.
[36]	DiNardo CD，Stein AS，Stein EM，et al.Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia[J].J Clin Oncol，2021，39（1）：57-65.
[37]	San José-Enériz E，Gimenez-Camino N，Agirre X，et al.HDAC Inhibitors in Acute Myeloid Leukemia[J].Cancers （Basel），2019，11（11）：1794.
[38]	Schlenk RF，Krauter J，Raffoux E，et al.Panobinostat monotherapy and combination therapy in patients with acute myeloid leukemia：results from two clinical trials[J].Haematologica，2018，103（1）：e25-e28.
[39]	Fiskus W，Buckley K，Rao R，et al.Panobinostat treatment depletes EZH2 and DNMT1 levels and enhances decitabine mediated de-repression of JunB and loss of survival of human acute leukemia cells[J].Cancer Biol Ther，2009，8（10）：939-950.
[40]	Gopalakrishnapillai A，Kolb EA，Mccahan SM，et al.Epigenetic drug combination induces remission in mouse xenograft models of pediatric acute myeloid leukemia[J].Leuk Res，2017，58：91-97.
[41]	Ocio EM，Herrera P，Olave MT，et al.Panobinostat as part of induction and maintenance for elderly patients with newly diagnosed acute myeloid leukemia：phase Ⅰb/Ⅱ panobidara study[J].Haematologica，2015，100（10）：1294-1300.
[42]	Walter RB，Medeiros BC，Gardner KM，et al.Gemtuzumab ozogamicin in combination with vorinostat and azacitidine in older patients with relapsed or refractory acute myeloid leukemia：a phase Ⅰ/Ⅱ study[J].Haematologica，2014，99（1）：54-59.
[43]	Craddock CF，Houlton AE，Quek LS，et al.Outcome of Azacitidine Therapy in Acute Myeloid Leukemia Is not Improved by Concurrent Vorinostat Therapy but Is Predicted by a Diagnostic Molecular Signature[J].Clin Cancer Res，2017，23（21）：6430-6440.
[44]	Ciftciler，Rafiye，Demiroglu，et al.Efficacy and Feasibility of Allogeneic Hematopoietic Stem-Cell Transplantation in the Treatment of Refractory Acute Myeloid Leukemia[J].Clin Lymphoma Myeloma Leuk，2019，19（3）：177-182.
[45]	Pei X，Huang X.New approaches in allogenic transplantation in AML[J].Semin Hematol，2019，56（2）：147-154.
[46]	Takami A.Hematopoietic stem cell transplantation for acute myeloid leukemia[J].Int J Hematol，2018，107（5）：513-518.
[47]	Saraceni F，Labopin M，Gorin NC，et al.Matched and mismatched unrelated donor compared to autologous stem cell transplantation for acute myeloid leukemia in first complete remission：a retrospective，propensity score-weighted analysis from the ALWP of the EBMT[J].J Hematol Oncol，2016，9（1）：1-14.
[48]	Gorin NC，Najman A，Duhamel G.Autologous bone-marrow transplantation in acute myelocytic leukaemia[J].Lancet，1977，309（8020）：1050.
[49]	Gorin NC，Giebel S，Labopin M，et al.Autologous stem cell transplantation for adult acute leukemia in 2015：time to rethink?Present status and future prospects[J].Bone Marrow Transplant，2015，50（12）：1495-1502.
[50]	Mizutani M，Hara M，Fujita HF，et al.Comparable outcomes between autologous and allogeneic transplant for adult acute myeloid leukemia in first CR[J].Bone Marrow Transplant，2016，51（5）：645-653.
[51]	Heini AD，Berger MD，Seipel K，et al.Consolidation with autologous stem cell transplantation in first remission is safe and effective in AML patients above 65 years[J].Leuk Res，2017，53：28-34.
[52]	Mueller BU，Seipel K，Bacher U，et al.Autologous Transplantation for Older Adults with AML[J].Cancers （Basel），2018，10（9）：340.